Tazarotene

Generic Name: Tazarotene

Brand Names: Arazlo, Duobrii, Fabior, Tazorac

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₁NO_₂S

CAS Number: 118292-40-3

Unique Ingredient Identifier: 81BDR9Y8PS

Background: Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).

Indication: Used to treat psoriasis, acne and sun damaged skin (photodamage).

Associated Conditions: Psoriasis Vulgaris (Plaque Psoriasis), Benign facial lentigines, Facial fine wrinkling, Facial hyperpigmentation, Facial hypopigmentation, Mild Acne vulgaris, Moderate Acne vulgaris

Associated Therapies: -

Clinical Trials

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

Phase 3

Active, not recruiting

Conditions: Acne Keloidalis Nuchae
AKN

Interventions: Drug: Placebo
Drug: Duobrii
Drug: Bryhali

First Posted Date: 2022-11-08

Last Posted Date: 2024-10-07

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 30

Registration Number: NCT05608499

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Duobrii in Combination With Biologics

Phase 4

Recruiting

Conditions: Psoriasis

Interventions: Drug: Duobrii

First Posted Date: 2019-10-08

Last Posted Date: 2020-04-30

Lead Sponsor: Psoriasis Treatment Center of Central New Jersey

Target Recruit Count: 25

Registration Number: NCT04119102

Locations: 🇺🇸
Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States

Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses

Not Applicable

Completed

Conditions: ACTINIC KERATOSES

Interventions: Drug: Tazorac

First Posted Date: 2010-01-21

Last Posted Date: 2015-08-11

Lead Sponsor: Stewart, Roger H., M.D., P.A.

Target Recruit Count: 10

Registration Number: NCT01053000

Locations: 🇺🇸
Roger Stewart MD PA, Fort Lauderdale, Florida, United States

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Tazaroc Gel
Drug: Tazarotene

First Posted Date: 2009-11-25

Last Posted Date: 2017-06-23

Lead Sponsor: Stiefel, a GSK Company

Target Recruit Count: 30

Registration Number: NCT01019603

Locations: 🇺🇸
DermResearch, Inc., Austin, Texas, United States

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Dapsone
Drug: Tazarotene

First Posted Date: 2009-02-03

Last Posted Date: 2011-10-31

Lead Sponsor: Allergan

Target Recruit Count: 171

Registration Number: NCT00834210

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back

Phase 2

Completed

Conditions: Skin Carcinoma

Interventions: Drug: tazarotene
Other: placebo

First Posted Date: 2008-11-02

Last Posted Date: 2016-02-11

Lead Sponsor: UCSF Benioff Children's Hospital Oakland

Target Recruit Count: 34

Registration Number: NCT00783965

Locations: 🇺🇸
Children's Hospital Oakland Research Institute, Oakland, California, United States
🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇺🇸
Children's Hospital Oakland Research Institiute, Oakland, California, United States

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

Phase 1

Conditions: Cutaneous T-Cell Lymphoma

First Posted Date: 2008-10-24

Last Posted Date: 2008-10-24

Lead Sponsor: McGill University

Target Recruit Count: 15

Registration Number: NCT00779896

Locations: 🇨🇦
McGill University, Montreal, Quebec, Canada

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails

Phase 4

Completed

Conditions: Brittle Nails

Interventions: Drug: Tazorac

First Posted Date: 2008-04-01

Last Posted Date: 2014-07-02

Lead Sponsor: Columbia University

Target Recruit Count: 20

Registration Number: NCT00648986

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

Phase 2

Completed

Conditions: Neoplastic Syndrome

Interventions: Drug: tazarotene

First Posted Date: 2007-06-21

Last Posted Date: 2020-10-29

Lead Sponsor: UCSF Benioff Children's Hospital Oakland

Target Recruit Count: 36

Registration Number: NCT00489086

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇺🇸
Children's Hospital and Research Center Oakland, Oakland, California, United States

The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance

Not Applicable

Completed

Conditions: Retinoid Intolerance
Sun-Damaged Skin

Interventions: Drug: Tazorac
Drug: Dove Mild Cleanser
Drug: Dove Facial Moisturizer

First Posted Date: 2007-02-26

Last Posted Date: 2020-03-13

Lead Sponsor: University of Michigan

Target Recruit Count: 40

Registration Number: NCT00440024

Locations: 🇺🇸
University of Michigan Department of Dermatology, Ann Arbor, Michigan, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy